van der Baan Bastiaan Jeroen 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Oct 16, 2023
Insider Transaction Report
Form 4
van der Baan Bastiaan Jeroen
Director
Transactions
- Award
Options to Purchase Common Stock
2023-09-26+250,000→ 250,000 totalExercise: $1.95Exp: 2028-09-26→ Common (250,000 underlying)
Holdings
- 25,000
Options to Purchase Common Stock
Exercise: $7.40From: 2022-06-17Exp: 2027-06-17→ Common (25,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying)
Footnotes (1)
- [F1]Explanation of Responses: in connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested. The Compensation Committee ratified the grant effective October 11, 2023.